Tag: Capital Royalty Partners L.P,NSCLC,Non-Small Cell Lung Cancer,Press Releases,Veristrat,blood-based cancer test,cancer diagnostics,liquid biopsy,oncology,serum protein test
-
Biodesix and Capital Royalty Close Financing Transaction
Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that the company closed a structured debt financing with Capital Royalty Partners L.P. The transaction provides Biodesix®with up to $20 million of capital.